AWMF Guideline No. 013/066: Diagnosis and therapy of localized scleroderma;AWMF-leitlinie nr. 013/066 diagnostik und therapie der zirkumskripten sklerodermie: Diagnostik und therapie der zirkumskripten sklerodermie

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue SUPPL. 6, 2009, Pages

  Kreuter, Alexander ^a   Krieg, Thomas ^b   Worm, Margitta ^c   Wenzel, Jörg ^d   Gambichler, Thilo ^a   Kuhn, Annegret ^e   Aberer, Elisabeth ^f   Scharffetter Kochanek, Karin ^g   Hunzelmann, Nicolas ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; CEFTRIAXONE; CENTROMERE ANTIBODY; CORTICOSTEROID; CREATINE KINASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; GLUCOCORTICOID; HISTONE ANTIBODY; IMIQUIMOD; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; PENICILLAMINE; PENICILLIN G; PIMECROLIMUS; PREDNISOLONE; RHEUMATOID FACTOR; SCL 70 ANTIBODY; UNINDEXED DRUG;

ATROPHIC SKIN DISEASE; BONE MARROW SUPPRESSION; DIFFERENTIAL DIAGNOSIS; DISABLING PANSCLEROTIC MORPHEA; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; EOSINOPHILIC FASCIITIS; HEMIFACIAL ATROPHY; HISTOPATHOLOGY; HUMAN; IDIOPATHIC ATROPHODERMA; LOW DRUG DOSE; LOW ENERGY RADIATION; MORPHEA; MORPHEA GUTTATA; NEPHROTIC SYNDROME; PHOTOTHERAPY; PHYSIOTHERAPY; PUVA; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; CHILD; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; SCLERODERMA, LOCALIZED; TREATMENT OUTCOME;

EID: 68149154608     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07178.x     Document Type: Review

References (79)

1. Akesson A, Hesseistrand R, Scheja A, Wildt M. Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic clerosis. Ann Rheum Dis 2004; 63:791-6.
2. Appenzeller S, Montenegro MA, Dertkigil SS, Sampaio-Barros PD, Marques-Neto JF, Samara AM, Andermann F, Cendes F. Neuroimaging findings in scleroderma en coup de sabre. Neurology 2004; 62: 1585-9.
3. Bendeck SE, Jacobe HT. Ultrasound as an outcome measure to assess disease activity in disorders of skin thickening: an example of the use of radiologic techniques to assess skin disease. Dermatol Ther 2007; 20: 86-92.
4. Birdi N, Shore A, Rush P, Laxer RM, Silverman ED, Krafchik B. Childhood linear scleroderma: a possible role of thermography for evaluation. J Rheumatol 1992; 19: 968-73.
5. Blaszczyk M, Janniger CK, Jablonska S. Childhood scleroderma and its peculiarities. Cutis 1996; 58: 141-4, 148-52.
6. Blaszczyk M, Królicki L, Krasu M, Glinska O, Jablonska S. Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol 2003; 30: 1997-2004.
7. Breuckmann F, Gambichler T, Altmeyer P, Kreuter A. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol 2004; 4:11.
8. Brinckmann J, Neess CM, Gaber Y, Sobhi H, Notbohm H, Hunzelmann N, Fietzek PP, Müller PK, Risteli J, Gebker R, Scharffetter-Kochanek K. Different pattern of collagen crosslinks in two sclerotic skin diseases: lipodermatosclerosis and circumscribed scleroderma. J Invest Dermatol 2001; 117:269-73.
9. Camacho NR, Sanchez JE, Martin RF, González JR, Sánchez JL. Medium-dose UVAl phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol 2001; 45: 697-9.
10. Christianson H, Dorsey C, O'Leary P, Kierland R. Localized scleroderma: a clinical study of two hundred thirtyfive cases. Arch Dermatol 1956; 74: 629-39.
11. Chung L, Lin J, Furst DE, Fiorentino D. Systemic and localized cleroderma. Clin Dermatol 2006; 24: 374-92.
12. Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998;39:211-5.
13. de Rie MA, Enomoto DN, de Vries HJ, Bos JD. Evaluation of mediumdose UVAl phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. Dermatology 2003; 207: 298-301.
14. Dytoc M, Ting PT, Man J, Sawyer D, Fiorillo L. First case series on the use of imiquimod for morphoea. Br J Dermatol 2005; 153: 815-20.
15. El-Mofty M, Mostafa W, El-Darouty M, Bosseila M, Nada H, Yousef R, Esmat S, El-Lawindy M, Assaf M, ElEnani G. Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. Photodermatol Photoimmunol Photomed 2004;20: 148-56.
16. Enomoto DN, Mekkes JR, Bossuyt PM, Hoekzema R, Bos JD. Quantification of cutaneous sclerosis with a skin elasticity meter in patients with generalized scleroderma. J Am Acad Dermatol 1996; 35: 381-7.
17. Falanga V, Medsger TA Jr. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol 1990; 126:609-12.
18. Fitch PG, Rettig P, Burnham JM, Finkel TH, Yan AC, Akin E, Cron RQ. Treatment of pediatric localized scleroderma with methotrexate. J Rheumatol 2006; 33: 609-14.
19. Gambichler T, Kreuter A, Hoffmann K, Bechara FG, Altmeyer P, Jansen T. Bilateral linear scleroderma "en coup de sabre" associated with facial atrophy and neurological complications. BMC Dermatol 2001; 1:9.
20. Haustein U, Mittag M. Morphea. In: Kerl H, Garbe C, Cerroni L, Wolff H. Histopathologie der Haut. 1. Auflage, Berlin: Springer, 2003: 457-9.
21. Grundmann-Kollmann M, Ochsendorf F, Zollner TM, Spieth K, Sachsenberg-Studer E, Kaufmann R, Podda M. PUVA-cream hotochemotherapy for the treatment of localized scleroderma. J Am Acad Dermatol 2000; 43: 675-8.
22. Gruss C, Reed JA, Altmeyer P, McNutt NS, Kerscher M. Induction of interstitial collagenase (MMP-1) by UVA-I phototherapy in morphea fibroblasts. Lancet. 1997; 350: 1295-6.
23. Hoffmann K, Gerbaulet U, el-Gammal S, Altmeyer P. 20-MHz B-mode ultrasound in monitoring the course of localized scleroderma (morphea). Acta Derm Venereol Suppl (Stockh) 1991; 164:3-16.
24. Holland KE, Steffes B, Nocton JJ, Schwabe MJ, Jacobson RD, Drolet BA. Linear scleroderma en coup de sabre with associated neurologic abnormalities. Pediatrics 2006; 117: el32-36.
25. Horger M, Fierlbeck G, KuemmerleDeschner J, Tzaribachev N, Wehrmann M, Claussen CD, Fritz J. MRI findings in deep and generalized morphea (localized scleroderma). AJR Am J Roentgenol 2008; 190: 32-9.
26. Hulshof MM, Bouwes Bavinck JN, Bergman W, et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000; 43: 1017-23.
27. Hunzelmann N, Anders S, Fierlbeck G, Hein R, Herrmann K, Albrecht M, Bell S, Muche R, Wehner-Caroli J, Gaus W, Krieg T. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 1997; 36: 433-5.
28. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995; 287: 193-7.
29. Ihn H, Yazawa N, Kubo M, et al. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol 2000; 27: 698-702.
30. Jablonska S (1975a) Facial hemiatrophy and it's relation to localized scleroderma. In: Jablonska S. Scleroderma and pseudoscleroderma. Warsaw: PZWL, 1975: 537-48.
31. Jablonska S (1975b) Localised Scleroderma. In: Jablonska S. Scleroderma and pseudoscleroderma. Warsaw: PZWL, 1975:277-303.
32. Jacobe HT, Cayce R, Nguyen J. UVAl phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-V. Br J Dermatol 2008; 159: 691-6.
33. Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Collagen. Rheum Dis Clin North Am 1996; 22: 647-74.
34. JoIy P, Bamberger N, Crickx B, Belaich S. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol 1994; 130: 663-4.
35. Kencka D, Blaszczyk M, Jablonska S. Atrophoderma Pasini-Pierini is a primary atrophic abortive morphea. Dermatology 1995; 190: 203-6.
36. Kerscher M, Meurer M, Sander C, Volkenandt M, Lehmann P, Plewig G, Röcken M. PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients. Arch Dermatol 1996; 132: 1280-2.
37. Kerscher M, Volkenandt M, Gruss C, Reuther T, von Kobyletzki G, Freitag M, Dirschka T, Altmeyer P. Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 1998; 38: 21-6.
38. Kreuter A, Gambichler T, Avermaete A, Jansen T, Hoffmann M, Hoffmann K, Altmeyer P, von Kobyletzki G, Bacharach-Buhles M. Combined treatment with calcipotriol ointment and low-dose ultraviolet Al phototherapy in childhood morphea. Pediatr Dermatol 2001; 18: 241-5.
39. Kreuter A, Gambichler T, Breuckmann F, Rotterdam S, Freitag M, Stuecker M, Hoffmann K, Altmeyer P. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 2005; 141: 847-52.
40. Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T A randomized controlled study of low-dose UVAl, medium-dose UVAl, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006; 54: 440-7.
41. Kroft EB, Berkhof NJ, Van De Kerkhof PC, Gerritsen RM, De Jong EM. Ultraviolet A phototherapy for sclerotic skin diseases: A systematic review. J Am Acad Dermatol 2008; 59: 1017-30.
42. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18:816-27.
43. Li SC, Liebling MS, Haines KA. Ultrasonography is a sensitive tool for monitoring localized scleroderma. Rheumatology 2007; 46: 1316-9.
44. Mancuso G, Berdondini RM. Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol 2005; 152: 180-2.
45. Martini G, Murray KJ, Howell KJ, Harper J, Atherton D, Woo P, Zulian F, Black CM. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology 2002; 41: 1178-82.
46. Marzano AV, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P, Caputo R. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol 2003; 13: 171-6.
47. McKee P, Calonje J, Granter S. Localized scleroderma. In: McKee PH, Calonje JE, Granter SR. Pathology of the Skin - with clinical correlations. 3rd ed. Mosby Ltd. 2005: 815-21.
48. Michet CJ Jr, Doyle JA, Ginsburg WW. Eosinophilic fasciitis: report of 15 cases. Mayo Clin Proc 1981; 56: 27-34.
49. Morita A, Kobayashi K, Isomura I, Tsuji T, Krutmann J. Ultraviolet Al (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000; 43: 670-4.
50. Mutzhas MF, Hölzle E, Hofmann C, Plewig G. A new apparatus with high radiation energy between 320-460 nm: physical description and dermatological applications. J Invest Dermatol 1981; 76: 42-47.
51. Peterson LS, Nelson AM, Su WP. Classification of morphea. Mayo Clin Proc. 1995;70:1068-1076.
52. Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmstedt county 1960-1993. J Rheumatol. 1997;24:73-80.
53. Rosenberg AM, Uziel Y, Krafchik BR, Hauta SA, Prokopchuk PA, Silverman ED, Laxer RM. Antinuclear antibodies in children with localized scleroderma. J Rheumatol 1995; 22: 2337-43.
54. Ruiz-Sandoval JL, Romero-Vargas S, Gutierrez-Aceves GA, GarciaNavarro V, Bernard-Medina AG, Cerda-Camacho F, Riestra-Castaneda R, Gonzalez-Cornejo S. Linear scleroderma en coup de sabre: neurological symptoms, images and review. Rev Neurol 2005; 41: 534-7 [Article in Spanish].
55. Sato S, Ihn H, Soma Y, Igarashi A, Tamaki T, Kikuchi K, Ishibashi Y, Takehara K. Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 1993; 36: 1137-41.
56. Scharffetter K, Wlaschek M, Hogg A, Bolsen K, Schothorst A, Goerz G, Krieg T, Plewig G. UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 1991; 283: 506-511.
57. Seidenari S, Conti A, Pepe P, Giannetti A. Quantitative description of echographic images of morphea plaques as assessed by computerized image analysis on 20 MHz B-scan recordings. Acta Derm Venereol 1995; 75: 442-5.
58. Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 1998;39:220-5.
59. Silman A, Jannini S, Symmons D, Bacon P. An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 1988; 27: 286-90.
60. Sommer A, Gambichler T, Bacharach-Buhles M, von Rothenburg T, Altmeyer P, Kreuter A. Clinical and serological characteristics of progressive facial hemiatrophy: a case series of 12 patients. J Am Acad Dermatol 2006; 54: 227-33.
61. Stege H, Berneburg M, Humke S, Klammer M, Grewe M, Grether-Beck S, Boedeker R, Diepgen T, Dierks K, Goerz G, Ruzicka T, Krutmann J. High-dose UVAl radiation therapy for localized scleroderma. J Am Acad Dermatol 1997; 36: 938-44.
62. Stein B, Rahmsdorf HJ, Steffen A, Litfin M, Herrlich P. UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. Mol Cell Biol 1989; 9: 5169-81.
63. Stone J. Parry-Romberg syndrome: a global survey of 205 patients using the Internet. Neurology 2003; 61: 674-6.
64. Sunderkötter C, Kuhn A, Hunzelmann N, Beissert S. Phototherapy: a promising treatment option for skin sclerosis in scleroderma? Rheumatology 2006; 45 Suppl 3, iii52-4.
65. Tollefson MM, Witman PM. En coup de sabre morphea and ParryRomberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol 2007; 56: 257-63.
66. Tuchinda C, Kerr HA, Taylor CR, Jacobe H, Bergamo BM, Elmets C, Rivard J, Lim HW. UVAl phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photodermatol Photoimmunol Photomed 2006; 22: 247-53.
67. Uziel Y, Krafchik BR, Silverman ED, Thorner PS, Laxer RM. Localized scleroderma in childhood: a report of 30 cases. Semin Arthritis Rheum 1994; 23: 328-40.
68. Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxer RM. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000; 136: 91-5.
69. Vierra E, Cunningham BB. Morphea and localized scleroderma in children. Semin Cutan Med Surg 1999; 18: 210-25.
70. Wang F, Garza LA, Cho S, Kafi R, Hammerberg C, Quan T, Hamilton T, Mayes M, Ratanatharathorn V, Voorhees JJ, Fisher GJ, Kang S. Effect of increased pigmentation on the antifibrotic response of human skin to UV-Al phototherapy. Arch Dermatol 2008; 144:851-8.
71. Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol 2006; 155: 1013-20.
72. Weibel L, Howell KJ, Visentin MT, Rudiger A, Denton CP, Zulian F, Woo P, Harper JI. Laser Doppler flowmetry for assessing localized scleroderma in children. Arthritis Rheum 2007; 56: 3489-95.
73. Weibel L, Harper JI. Linear morphoea follows Blaschko's lines. Br J Dermatol 2008; 159: 175-81.
74. Wienecke R, Schlüpen EM, Zöchling N, Neubert U, Meurer M, Volkenandt M. No evidence for Borrelia burgdorferi-specific DNA in lesions of localized scleroderma. J Invest Dermatol 1995; 104:23-6.
75. Wlaschek M, Wenk J, Brenneisen P, Briviba K, Schwarz A, Sies H, Scharffetter-Kochanek K. Singlet oxygen is an early intermediate in cytokinedependent ultraviolet-A induction of interstitial collagenase in human dermal fibroblasts in vitro. FEBS Lett 1997;413:239-42.
76. Yin L, Yamauchi R, Tsuji T, Krutmann J, Morita A. The expression of matrix metalloproteinase-l mRNA induced by ultraviolet Al (340-400 nm) is phototherapy relevant to the glutathione (GSH) content in skin fibroblasts of systemic sclerosis. J Dermatol 2003; 30: 173-80.
77. Zannin ME, Martini G, Athreya BH, Russo R, Higgins G, Vittadello F, Alpigiani MG, Alessio M, Paradisi M, Woo P, Zulian F; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Ocular involvement in children with localised scleroderma: a multi-centre study. Br J Ophthalmol 2007; 91: 1311-4.
78. Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, Espada G, Corona F, Mukamel M, Vesely R, Musiej-Nowakowska E, Chaitow J, Ros J, Apaz MT, Gerloni V, MazurZielinska H, Nielsen S, Ullman S, Horneff G, Wouters C, Martini G, Cimaz R, Laxer R, Athreya BH; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005; 52:2873-81.
79. Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG, Cuttica R, Higgins GC, Van Suijlekom-Smit LW, Moore TL, Lindsley C, Garcia-Consuegra J, Esteves Hilário MO, Lepore L, Silva CA, Machado C, Garay SM, Uziel Y, Martini G, Foeldvari I, Peserico A, Woo P, Harper J; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology 2006; 45: 614-20.